Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3511-I
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
3511-I is a novel small-molecule inhibitor targeting EphB2 (Ephrin type-B receptor 2). Preclinical studies in a mouse model of unilateral renal ischemia-reperfusion (IR) injury demonstrated that treatment with 3511-I significantly attenuated kidney injury and fibrosis. Its mechanism involves promoting tubular repair and suppressing sustained inflammatory signaling, similar to the effects observed with tubular-specific genetic deletion of EphB2.
Beyond the preview
Go deeper on 3511-I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3511-I.